Ranibizumab (Lucentis)

A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.

Also Known As:

Networked: 3292 relevant articles (499 outcomes, 886 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bressler, Neil M: 51 articles (01/2022 - 11/2007)
2.	Bandello, Francesco: 45 articles (01/2022 - 11/2010)
3.	Souied, Eric H: 40 articles (03/2022 - 02/2008)
4.	Glassman, Adam R: 38 articles (12/2021 - 12/2009)
5.	Querques, Giuseppe: 34 articles (05/2020 - 02/2008)
6.	Schmidt-Erfurth, Ursula: 33 articles (05/2020 - 12/2007)
7.	Brown, David M: 33 articles (01/2019 - 10/2006)
8.	Kaiser, Peter K: 32 articles (01/2022 - 10/2006)
9.	Jampol, Lee M: 31 articles (05/2020 - 07/2014)
10.	Campochiaro, Peter A: 29 articles (10/2022 - 12/2006)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 01/01/2013 - "Wet age-related macular degeneration (AMD) treatment using intravitreal ranibizumab needs to be started as soon as possible and treatment must be administered based on regular review to achieve the best results. " 01/01/2012 - "Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection." 04/01/2019 - "In this study, conducted in real-world clinical practice with a large number of neovascular age-related macular degeneration patients, visual and anatomical outcomes improved significantly after three monthly ranibizumab treatments. " 12/01/2011 - "Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a ≥ 3-line BCVA loss during the first year of treatment." 07/01/2014 - "and (2) Is a higher dose of ranibizumab (2.0 mg/0.05 mL) more effective in treating PCV than the current dose (0.5 mg/0.05 mL) approved for treatment of age-related macular degeneration? "
2.	Macular Edema 01/01/2017 - "Intravitreal ranibizumab (RBZ) has been shown in multiple randomized clinical trials to be a valuable treatment for diabetic macular edema (DME), promoting a significant improvement in best-corrected visual acuity (BCVA) and in anatomic outcomes. " 01/01/2021 - "Intravitreal ranibizumab for diabetic macular edema was effective in a real-world clinical setting, with most eyes gaining or maintaining vision. " 01/01/2015 - "Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. " 12/01/2019 - "The rates of clinically significant DR improvement with ranibizumab could be twice that in the subgroup of patients with moderately severe or severe nonproliferative DR and macular edema. " 04/01/2016 - "We observed that ranibizumab significantly improved visual acuity after 3 and 6 months from the beginning of the treatment, which was a consequence of reduced macular edema and vascular leakage. "
3.	Choroidal Neovascularization 07/01/2021 - "Ranibizumab 0.5 mg treatment was beneficial in improving visual acuity and stabilizing or reducing central subfield thickness in five adolescents with differing choroidal neovascularization etiologies requiring infrequent injection. " 05/01/2012 - "We report the first case of choroidal neovascularization associated with Strüpell-Lorrain syndrome treated successfully with intravitreal ranibizumab injection." 09/01/2012 - "Intravitreal ranibizumab and IVB are effective in the treatment of subfoveal myopic choroidal neovascularization. " 05/01/2012 - "Intravitreal ranibizumab may be effective to induce morphological and functional improvement in cases of choroidal neovascularization secondary to adult-onset vitelliform foveomacular dystrophy. " 11/01/2017 - "Intravitreal ranibizumab was safe and effective for treating myopic choroidal neovascularization. "
4.	Retinal Vein Occlusion 05/01/2013 - "Early ranibizumab responders had excellent visual outcomes regardless of ranibizumab dose; mean improvement in BCVA letter score at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]). " 07/09/2020 - "The objective of our study was to assess the efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion (BRVO). " 07/09/2020 - "Efficacy of intravitreal Lucentis injection on major and macular branch retinal vein occlusion." 05/01/2013 - "In retinal vein occlusion, both ranibizumab and Ozurdex have been shown to be effective, although their relative efficacy has not been determined in head-to-head clinical trials. " 08/01/2017 - "According to our results intravitreal ranibizumab is a safe and effective treatment for ME caused by retinal vein occlusion. "
5.	Diabetic Retinopathy (Retinopathy, Diabetic) 01/01/2019 - "Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies." 09/01/2007 - "The efficacy of ranibizumab has been studied in 3 large clinical trials having the same primary efficacy end point, the proportion of patients losing <15 letters from baseline at 12 months (Early Treatment of Diabetic Retinopathy Study chart). " 04/01/2019 - "Efficacy of ranibizumab for the treatment of diabetic retinopathy: A protocol for systematic review of randomized controlled trial." 01/01/2012 - "The mean visual acuity in the ranibizumab alone group improved from 52.9 Early Treatment of Diabetic Retinopathy letters initially to 62.8 letters at twelve months. " 08/04/2023 - "PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis. "

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	aflibercept
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Ranibizumab (Lucentis)
5.	Dexamethasone (Maxidex)
6.	Retinaldehyde (Retinal)
7.	1-phenyl-3,3-dimethyltriazene (PDT)
8.	Verteporfin (Visudyne)
9.	KH902 fusion protein
10.	pegaptanib (Macugen)

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Therapeutics
3.	Injections
4.	Lasers (Laser)
5.	Photochemotherapy (Photodynamic Therapy)